Six Peptides, One New Policy: What Changed in October 2026

If you follow peptides, you've probably seen headlines saying BPC-157 and others are "legal now." The real story is more careful than that. Here's what happened, in plain English.

The short version

On October 28, 2026, the U.S. Department of Health and Human Services (HHS) released a policy covering six peptides: BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon. HHS said it does not plan to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound these six, as long as a list of conditions is met. The policy was published in the Federal Register on October 30.

That opens a federal path for licensed compounding pharmacies to prepare these peptides with a prescription. State pharmacy rules still apply. It does not make them FDA-approved drugs.

How we got here

• February 2026: HHS Secretary Robert F. Kennedy Jr. said in a February 27 podcast interview that he wanted about 14 of the 19 restricted peptides moved back to a list pharmacies can compound from.
• April 2026: The FDA removed 12 peptides from "Category 2," its list of substances that raise significant safety risks, after the groups that nominated them withdrew their nominations. Coming off that list did not, by itself, allow compounding.
• July 2026: An FDA advisory committee voted, by narrow margins (between 7-4 and 8-6), to recommend six peptides for the official list pharmacies can compound from. It voted against a seventh, emideltide (also called DSIP). FDA's own scientific staff had recommended against all seven.
• October 2026: HHS issued the new policy for those six, before any formal FDA rulemaking.

What the policy does NOT do

This part matters most.

• It is not FDA approval. None of these six peptides is an FDA-approved drug.
• It is not permanent. It lasts until the FDA decides, through formal rulemaking, which peptides go on the official list. HHS said it may revisit the policy if safety or quality problems appear. HHS took public comments on it until November 13, 2026, so details may change.
• It still requires a prescription for a specific patient from a licensed provider.
• It has conditions. For example, the raw ingredient must come from an FDA-registered manufacturer with a certificate of analysis, the product must be labeled as compounded and not for resale, and serious side effects must be reported to the FDA.
• It does not cover "research use only" peptides sold online. Those are not made under these rules.
• It came from HHS, not the FDA. Some consumer and safety groups have objected, and legal experts are watching how it plays out.

What about the research?

A policy change is not new science. For most of these peptides, research in people is still limited. Much of the evidence comes from animal and lab studies or small human studies. FDA's scientific staff pointed to limited safety and effectiveness information for all of them. Whether they work, and how safe they are, is not yet known, and it's worth being honest about that.

What this means for you

If you're curious about any of these peptides:

1. Talk to a licensed provider. Only they can decide if a compounded peptide is right for you and write a prescription.
2. Ask where it's made. A licensed compounding pharmacy working under these rules is very different from an online "research" seller.
3. Know the evidence. Ask what's been studied in people, not just in animals.

How The Pep Report fits in

The Pep Report looks at what your DNA may reveal about you, then shows the peptides and supplements research has studied for the health goals you choose. If one of these six shows up in your report, you'll see what's been studied and how strong the evidence is, labeled plainly, along with its current FDA status. The Pep Report doesn't sell or prescribe peptides. We're planning The Pep Clinic, where independent licensed providers would review your report and decide whether a treatment is right for you. It isn't open yet.

We'll update this post as the FDA moves forward.

This article is for education only. It is not medical or legal advice. Talk with a licensed healthcare provider before starting any peptide or supplement.

Sources: HHS, "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances," Federal Register, Oct. 30, 2026 (FR Doc. 2026-22192), and the HHS policy document (hhs.gov); FDA Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026; FDA notice on Category 2 peptides, April 15, 2026.